Photo of Primo Lara taken from ucdavis.edu
Sep 29, 2024, 09:49
Adjuvant Everolimus in Patients with Completely Resected, High-risk Renal Cell Carcinoma – European Urology
European Urology shared on X:
“Platinum Priority – Kidney Cancer: Adjuvant Everolimus in Patients with Completely Resected, Very High-risk Renal Cell Carcinoma of Clear Cell Histology: Results from the Phase 3 Placebo-controlled SWOG S0931 (EVEREST) Trial by Primo Lara et al.
Read the full article here.
Come back tomorrow for the Editorial!
Authors: Primo N. Lara, Catherine Tangen, Elisabeth I. Heath, Shuchi Gulati, Mark N. Stein, Maxwell Meng, Ajjai Shivaram Alva, Sumanta K. Pal, Igor Puzanov, Joseph I. Clark, Toni K. Choueiri, Neeraj Agarwal, Robert Uzzo, Naomi B. Haas, Timothy W. Synold, Melissa Plets, Ulka N. Vaishampayan, Brian M. Shuch, Seth Lerner, Ian M. Thompson, Christopher W. Ryan
Source: European Oncology/X
Ajjai Shivaram Alva
Brian M. Shuch
cancer
Catherine Tangen
Christopher W Ryan
Elisabeth I. Heath
Ian M. Thompson
Igor Puzanov
Joseph I. Clark
kidney cancer
Mark N. Stein
Maxwell Meng
Melissa Plets
Naomi B Haas
Neeraj Agarwal
OncoDaily
Oncology
Primo N Lara
renal cell carcinoma
Robert Uzzo
Seth Lerner
Shuchi Gulati
Sumanta K. Pal
Timothy W. Synold
Toni K. Choueiri
Ulka N. Vaishampayan
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 21, 2024, 09:55
Nov 21, 2024, 09:28
Nov 21, 2024, 09:23
Nov 21, 2024, 09:04
Nov 21, 2024, 06:49